Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players...市場調査レポートについてご紹介

Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players (Code:GBIR403170017)


Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players


GBI Research, the leading business intelligence provider, has released its latest research “Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%.

Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. Price reviews are also constrained by a national health budget, which limits the increase of drug prices. In addition, the gradual increase in market share and competition from generics has depressed market value and will continue to do so as government policy promotes their use.

However, easing of regulatory guidelines, an aging population and a strong product pipeline will provide a strong impetus for growth in the pharmaceutical industry. Although the increasing market share of generics may dampen market value, this represents a great deal of opportunity for generic manufacturers.

Historically, the Japanese pharmaceutical market has favored domestic companies. However, since the 1990s, deregulation has promoted investment from abroad and increased the presence of foreign firms.


– The report assesses characteristics of the Japanese pharmaceutical market, detailing recent regulatory changes, supply chain and competitive landscape. It also draws on macroeconomic and demographic factors and the implications on healthcare policy.
– A macroeconomic analysis of Japan, focusing on key economic parameters such as Gross Domestic Product (GDP), inflation and unemployment. The implications of the global financial crisis in 2008 and natural disaster in 2011 are considered.
– The changing demographic landscape and implications on health economics and policy-making.
– The industry characteristics section presents an overview of pricing policies, the regulatory landscape, new drug approval process and pharmaceutical supply chain in Japan. Notable changes that have occurred over recent years, in an attempt to improve the regulatory system and reduce drug review times, are highlighted.
– The report then analyzes the competitive landscape in Japan, including the major domestic companies and M&A. The discussed regulatory reforms and cooperation between government and industry have improved the international competitiveness of Japan’s pharmaceutical market. Coupled with a number of mergers, the industry now consists of well-known multinationals. The competitive landscape section confirms the top five Japanese pharmaceutical companies by revenue, according to GBI Research data.
– The report concludes by providing an overview of the drivers and barriers currently facing the Japanese pharmaceutical industry.

Reasons to buy

– Primarily, the report will allow clients to gain a strong understanding of the economic and healthcare challenges facing Japan.
– In addition, the report will assist in identifying opportunities within Japan’s pharmaceutical market, including:
– Potential for market growth – A number of factors could provide strong potential for sales growth in the Japanese pharmaceutical market. Examples include the world leading life expectancy and associated increase in lifestyle diseases, and government initiatives to prevent such diseases, which provides opportunities for healthcare and pharmaceutical companies, who often carry out the work.
– The report provides a source of information covering Japan’s regulatory landscape, and importantly, recent deregulation, to help identify the reasons Japan has become an attractive market for big pharma.
– The report will provide new market entrants with a comprehensive overview of the leading Japanese pharmaceutical companies, and the specific therapeutic indications they are currently targeting.
– Overall, allowing clients to determine whether the Japanese pharmaceutical market will provide them with commercially viable opportunities for growth.






1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
3 Market Overview 11
3.1 Introduction 11
3.2 Economic Landscape 11
3.3 Economic Indicators 12
3.3.1 Gross Domestic Product 12
3.3.2 GDP Composition by Sector 15
3.3.3 Consumer Price Index 16
3.3.4 Unemployment 18
3.3.5 Exchange Rate 20
3.3.6 Foreign Direct Investment 21
3.3.7 Trade Balance 23
3.3.8 Value of Exports/Imports 24
3.3.9 Exports and Imports Forecast 25
3.3.10 Trading Partners 26
3.3.11 Government Debt 27
3.3.12 Gross National Income 28
3.3.13 Gross National Savings 31
3.3.14 Labor Force 32
3.3.15 Employment 34
3.3.16 Current Account Balance 36
3.3.17 Foreign Exchange Reserves 37
3.4 Demographic Analysis 38
3.4.1 Population 38
3.4.2 Population Distribution 39
3.4.3 Urban-Rural Share 40
3.5 Healthcare 41
3.5.1 Healthcare Expenditure 41
3.5.2 Public and Private Expenditure 43
3.5.3 Healthcare Infrastructure 46
3.5.4 Alcohol Consumption 49
3.5.5 Tobacco Consumption 50
3.5.6 Obesity 52
3.5.7 Life Expectancy 53
3.5.8 Leading Causes of Death 54
3.5.9 Pharmaceutical Expenditure 55
3.5.10 Insurance and Reimbursement 55
3.5.11 Reimbursement Process 57
3.6 Market Segments 58
3.6.1 Generics 58
3.6.2 Over-the-Counter Drugs 59
4 Industry Characteristics 60
4.1 Introduction 60
4.2 Pricing Policy 60
4.2.1 Reimbursement Prices for New Drugs 60
4.3 Regulatory Landscape 62
4.3.1 Pharmaceutical and Food Safety Bureau 64
4.3.2 Pharmaceutical and Medical Devices Agency 65
4.3.3 New Drug Approval Process 66
4.3.4 Drug Manufacture 68
4.3.5 Clinical Trials – Basic Requirements 68
4.3.6 Advertising 68
4.3.7 Licensing 69
4.3.8 Orphan Drugs 69
4.4 Pharmaceutical Supply Chain 70
4.4.1 Leading Companies 71
5 Competitive Landscape 72
5.1 Introduction 72
5.2 Major Domestic Companies 72
5.2.1 Major Players by Revenue 72
5.2.2 Takeda 73
5.2.3 Product Portfolio 73
5.2.4 Research and Development 73
5.2.5 Otsuka 76
5.2.6 Product Portfolio 76
5.2.7 Research and Development 77
5.2.8 Astellas 78
5.2.9 Product Portfolio 79
5.2.10 Research and Development 80
5.2.11 Daiichi Sankyo 81
5.2.12 Product Portfolio 81
5.2.13 Research and Development 82
5.2.14 Eisai 83
5.2.15 Research and Development 84
5.3 Major Foreign Players 85
5.4 Acquisitions and Collaboration 86
5.4.1 M&A 86
5.4.2 Licensing Agreements and Co-development Deals 89
6 Drivers and Barriers 92
6.1 Drivers 92
6.1.1 World-Leading Life Expectancy – Increased Disease Burden 92
6.1.2 Deregulation – Easing of Regulatory Guidelines 92
6.1.3 Government Initiatives to Prevent Lifestyle Diseases 92
6.1.4 Continued Growth of the Generics Market 92
6.2 Barriers 93
6.2.1 Time Lag in Drug Approval Process 93
6.2.2 Political Instability 93
6.2.3 High Cost of Clinical Trials 93
6.2.4 High Value of the Yen 93
7 Japan Pharmaceutical Market Outlook – Appendix 94
7.1 Market Definitions 94
7.2 Abbreviations 94
7.3 Bibliography 95
7.4 Research Methodology 96
7.5 Coverage 96
7.6 Secondary Research 97
7.7 Competitive Landscape 97
7.7.1 Expert Panel Validation 97
7.8 Contact Us 97
7.9 Disclaimer 97






■ タイトル:Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players
■ 発行日:2013年4月29日
■ 調査会社:GBI Research
■ 商品コード:GBIR403170017
■ 調査対象地域:日本

Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players ( / GBIR403170017)

  • アフェクティブコンピューティングの世界市場予測(~2021)
    MarketsandMarkets forecasts the affective computing market size to grow from USD 12.20 Billion in 2016 to USD 53.98 Billion by 2021, at an estimated Compound Annual Growth Rate (CAGR) of 34.7%. Major factors contributing to the growth of the market are the increasing adoption of human and machine interaction technologies. The global affective computing market is segmented by technology, software, …
  • オンライン映画の世界市場2016-2020
    About Online Movies Online movies refer to the service wherein individuals can watch movies on a digital platform using the Internet. This platform enables individuals to watch movies anytime and at any place without a fixed scheduled time, which provides users complete control over the content. Online movies can be watched by streaming, downloading, or subscribing on a monthly basis. With the eme …
  • Rex Energy Corporation:石油・ガスの開発・生産動向及びコスト分析- Q1, 2013
    Rex Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Rex Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
  • 世界のルチル市場2015
    The Global Rutile Industry Report 2015 is a professional and in-depth study on the current state of the Rutile industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Rutile market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regio …
  • スマート包装の世界市場分析:製品別(アクティブパッケージング、インテリジェントパッケージング)、用途別(食品・飲料、ヘルスケア、パーソナルケア、自動車)、セグメント予測
    The global smart packaging market is expected to reach USD 26.7 billion by 2024, according to a new report by Grand View Research, Inc. Rising need for smart packaging products owing to increasing usage in the end use industries such as electronics and automotive on account of its superior protection properties is expected to fuel the growth over the forecast period. Rising industrialization in em …
  • VoLTEの世界市場2015-2019
    About VoLTE VoLTE or Voice over long-term evolution is a technology that enables voice calls over an LTE network, as opposed to earlier voice calls in use over 2G and 3G networks. This is quite similar to voice over internet protocol (VoIP), used to support voice calls over a broadband connection. Unlike VoIP that sends voice over circuit-switched networks, VoLTE sends voice calls over IP-based LT …
  • グローバルIPTV市場動向
    Product Synopsis We estimate that the 100-millionth IPTV customer globally came online in November 2013. China, France and the US together account for over half of all subscriptions, but penetration levels vary greatly. We expect global IPTV revenue to rise at a 11.8% CAGR from 2013 to 2018. A blend of primary research, market indicators and qualitative analysis, our IPTV Research in Focus helps i …
  • National Refinery Limited:石油・ガスバリューチェーン分析レポート2013
    National Refinery Limited Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "National Refinery Limited" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “National Refinery Limited”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. …
  • クラウド及びウェアラブル技術におけるHCM(人材管理)市場
    Human Capital Management (HCM) is the process of aligning all human resource management related functions in a unified and integrated solution that start with the perception of viewing employee as asset or human capital. In the back office, HCM is either a component of an enterprise resource planning (ERP) system or a separate suite that is typically integrated with the ERP. The use of Cloud-based …
  • 自動トラック積載装置の世界市場
    About Automated Truck Loading SystemAutomated truck loading systems (ATLS) are used to load trucks and trailers and are used to ensure material handling operations are faster, safer, and have low operational costs. An ATLS comprises two components: the trailer system in the truck trailer and the dock system in the loading ramp. They are majorly used for one-way loading and shuttle transportation. …
  • 低電圧MOSFETのグローバル市場動向(2014-2018)
    About Low-voltage MOSFETs A MOSFET is a three terminal semiconductor component and a type of transistor which is used for amplifying electronic signals or switching electronic signals. MOSFETs are mainly used for voltage conversions. MOSFETs are basically silicon-based semiconductor components used in electronic devices. Further, MOSFETs have three terminals namely source, gate, and drain. A low-v …
  • Exelon (Alzheimer’s Disease):市場予測と分析(~2022)
    Exelon (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Exelon (Alzheimer’s Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are re …
  • 高純度アルミナの世界市場2016-2020
    About Alumina Alumina, commonly known as Al2O3, is primarily used as a feedstock for the fabrication of metallic aluminum, known as smelter grade alumina (SGA). Approximately 90% of alumina is used in aluminum fabrication, and the remaining 10% is dedicated to the non-metallurgical market for industrial use. High-purity alumina, which characterizes alumina with a minimum purity of 99.99%, is the h …
  • 寒冷式疼痛治療の世界市場予測(~2021年):OTC医薬品、医療機器、処方薬
    Cold pain therapy is among the most commonly adopted methods for the temporary management of pain and inflammation, sprains, strains, bumps, bruises, and arthritis. Pharmaceuticals used for cold pain therapy have menthol as their active ingredient (with menthol content of 1% and above), whereas medical devices have ice or cold water as their key component. Menthol in topical analgesics acts as a c …
  • 世界のスマート教室市場:Global Smart Classroom Market 2014-2018
    TechNavio's analysts forecast the Global Smart Classroom market to grow at a CAGR of 31.25 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increased market for interactive display instruments. The Global Smart Classroom market has also been witnessing the growing importance of 3D education. However, the high implementation cost could pose a chall …